Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

Underweight TAVR patients face higher mortality risk—obesity makes no significant impact

Reviewing data from more than 6,000 patients, researchers found little evidence of the "obesity paradox" observed elsewhere. Underweight TAVR patients, however, may face some significant long-term risks.

Society of Cardiovascular Angiography and Interventions (SCAI) President James B. Hermiller, Jr., MD, director of the transcatheter structural heart program at Ascension St. Vincent Heart Center in Indianapolis, explains SCAI's push for wider adoption of new, innovative cath lab radiation protection technology to reduce radiation exposure and the need for lead aprons that cause orthopedic injury.

SCAI pushes for better radiation protection in cath labs

Society of Cardiovascular Angiography and Interventions President James Hermiller, Jr., MD, explains SCAI's push for wider adoption of new, innovative cath lab radiation protection technology to reduce radiation exposure and the need for lead aprons.

Meril Life Sciences, an India-based medical device company founded in 2006, developed the Myval TAVR valve

Myval TAVR valve non-inferior to Sapien 3 after 1 year—pacemaker implants the biggest difference

India-based Meril Life Sciences has been manufacturing its Myval transcatheter heart valves for years, but the technology has not yet gained FDA approval. This latest head-to-head comparison included data from more than 1,000 TAVR patients.

Medtronic Evolut FX TAVR valve

Oversizing reduces PVL when implanting Medtronic’s newer self-expanding TAVR valves

Paravalvular leak has been shown to impact patient outcomes after TAVR. Higher degrees of valve oversizing, however, can reduce the risk of post-treatment PVL without increasing the odds of adverse outcomes.

Edwards Lifesciences INSPIRIS RESILIA Aortic Valve

Resilia tissue developed by Edwards Lifesciences linked to long-term benefits

Researchers tracked nearly 1,000 SAVR patients, presenting eight-year data at the Heart Valve Society’s annual meeting in Cairo, Egypt. 

Solo Pace Incorporated SoloPace Control System

Cardiologist-founded startup announces FDA clearance, first uses of new TAVR pacing system

“The device takes variability out of the procedure by giving the operator full control while automating ramp-up and back-up algorithms," according to a clinician who used the new technology. "The TAVR procedure is simplified, reducing physician and staff workload."

cardiologist viewing heart data

Death after 1 year more common for real-world low-risk TAVR patients than those treated in clinical trials

Real-world patients were still associated with "excellent" outcomes, but it is important for cardiologists and patients alike to know as much as possible about the odds of survival following treatment. 

LUMA Vision Verafeye Visualization Platform

FDA clears catheter-based 4D visualization platform for complex heart procedures

The new technology from LUMA Vision allows operators to deliver 2D and 4D ultrasound images in real time. The advanced catheter was built with maneuverability and increased visibility in mind.

Displaying 105 - 112 of 1063
Design by Adaptive Theme